Targeted therapy for breast cancer prevention

Frontiers in Oncology

Volumn 3 SEP, Issue , 2013, Pages

  den Hollander, Petra ^a   Savage, Michelle I ^a   Brown, Powel H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast; Cancer; Prevention; Therapy; TNBC

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL) AMINO] PYRROLO [2, 1 F] [1, 2, 4] TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; 1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; 6 [1 (5, 6, 7, 8 TETRAHYDRO 3, 5, 5, 8, 8 PENTAMETHYL 2 NAPHTHYL) CYCLOPROPYL] NICOTINIC ACID; ANASTROZOLE; BEXAROTENE; CELECOXIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; FENRETINIDE; GEFITINIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOTRETINOIN; LAPATINIB; LASOFOXIFENE; LETROZOLE; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PLACEBO; PROGESTERONE RECEPTOR; RALOXIFENE; RAPAMYCIN; RETINOIC ACID RECEPTOR; RETINOID; RIDAFOROLIMUS; TAMOXIFEN; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CATARACT; CHEMOPROPHYLAXIS; DISEASE ASSOCIATION; DRUG MEGADOSE; ENDOMETRIUM CANCER; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; GENE EXPRESSION; HER2 POSITIVE BREAST CANCER; HIGH RISK POPULATION; HOT FLUSH; HUMAN; INTRADUCTAL CARCINOMA; LONG TERM CARE; LOW DRUG DOSE; MAJOR HISTOCOMPATIBILITY COMPLEX; MAXIMUM TOLERATED DOSE; META ANALYSIS (TOPIC); NIGHT SWEAT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; THROMBOEMBOLISM; TRIPLE NEGATIVE BREAST CANCER;

EID: 84891119238     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00250     Document Type: Article

References (133)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin (2013) 63:11-30. doi:10.3322/caac.21166
2. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control (1994) 5:491-500. doi:10.1007/BF01831376
3. Sprague BL, Trentham-Dietz A, Remington PL. The contribution of postmenopausal hormone use cessation to the declining incidence of breast cancer. Cancer Causes Control (2011) 22:125-34. doi:10.1007/s10552-010-9682-7
4. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet (2012) 380:1778-86. doi:10.1016/S0140-6736(12)61611-0
5. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature (2000) 406:747-52. doi:10.1038/35021093
6. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 98:10869-74. doi:10.1073/pnas.191367098
7. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 100:10393-8. doi:10.1073/pnas.1732912100
8. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 8:R76. doi:10.1186/gb-2007-8-5-r76
9. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 12:R68. doi:10.1186/bcr2635
10. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 121:2750-67. doi:10.1172/JCI45014
11. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (2011) 378:771-84. doi:10.1016/S0140-6736(11)60993-8
12. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet (2003) 361:296-300. doi:10.1016/S0140-6736(03)12342-2
13. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst (2007) 99:283-90. doi:10.1093/jnci/djk050
14. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (2005) 97:1652-62. doi:10.1093/jnci/dji372
15. Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy. J Natl Cancer Inst (2007) 99:727-37. doi:10.1093/jnci/djk154
16. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst (2007) 99:272-82. doi:10.1093/jnci/djk049
17. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA (1999) 281:2189-97.
18. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 96:1751-61. doi:10.1093/jnci/djh319
19. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med (2006) 355:125-37. doi:10.1056/NEJMoa062462
20. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA (2006) 295:2727-41. doi:10.1001/jama.295.23.joc60074
21. Cummings SR, Ensrud K, Delmas PD, Lacroix AZ, Vukicevic S, Reid DM, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med (2010) 362:686-96. doi:10.1056/NEJMoa0808692
22. Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther (2008) 8:1377-85. doi:10.1586/14737140.8.9.1377
23. Goss PE, Richardson H, Chlebowski R, Johnston D, Sarto GE, Maunsell E, et al. National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: evaluation of exemestane to prevent breast cancer in postmenopausal women. Clin Breast Cancer (2007) 7:895-900. doi:10.3816/CBC.2007.n.057
24. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 364:2381-91. doi:10.1056/NEJMoa1103507
25. Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, et al. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer (2011) 117:39-47. doi:10.1002/cncr.25399
26. Decensi A, Puntoni M, Pruneri G, Guerrieri-Gonzaga A, Lazzeroni M, Serrano D, et al. Lapatinib activity in premalignant lesions and T cancer of the breast in a randomized, placebo-controlled presurgical trial. Cancer Prev Res (Phila) (2011) 4:1181-9. doi:10.1158/1940-6207.CAPR-10-0337
27. Brown P, Arun B, Miller A, Isaacs C, Gutierrez C, Huang J, et al. Abstract CN04-04: phase II trial of bexarotene in women at high risk of breast cancer: comparison of protein and RNA biomarkers. Cancer Prev Res (2008) 1:CN04-04. doi:10.1158/1940-6207.PREV-08-CN04-04
28. Powles TJ, Hardy JR, Ashley SE, Farrington GM, Cosgrove D, Davey JB, et al. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer (1989) 60:126-31. doi:10.1038/bjc.1989.235
29. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet (1998) 352:98-101. doi:10.1016/S0140-6736(98)85012-5
30. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 90:1371-88. doi:10.1093/jnci/90.18.1371
31. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet (1998) 352:93-7. doi:10.1016/S0140-6736(98)04394-3
32. Cuzick J, Forbes J, Edwards R, Baum M, Cawthorn S, Coates A, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet (2002) 360:817-24. doi:10.1016/S0140-6736(02)09962-2
33. Vogel VG, Qu Y, Wong M, Mitchell B, Mershon JL. Incidence of invasive breast cancer in postmenopausal women after discontinuation of long-term raloxifene administration. Clin Breast Cancer (2009) 9:45-50. doi:10.3816/CBC.2009.n.008
34. Grady D, Cauley JA, Geiger MJ, Kornitzer M, Mosca L, Collins P, et al. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst (2008) 100:854-61. doi:10.1093/jnci/djn153
35. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 trial: preventing breast cancer. Cancer Prev Res (Phila) (2010) 3:696-706. doi:10.1158/1940-6207.CAPR-10-0076
36. Haynes BP, Dowsett M, Miller WR, Dixon JM, Bhatnagar AS. The pharmacology of letrozole. J Steroid Biochem Mol Biol (2003) 87:35-45. doi:10.1016/S0960-0760(03)00384-4
37. Sasano H, Miki Y, Shibuya R, Suzuki T. Aromatase and in situ estrogen production in DCIS (ductal carcinoma in situ) of human breast. J Steroid Biochem Mol Biol (2010) 118:242-5. doi:10.1016/j.jsbmb.2009.09.008
38. Cuzick J. Aromatase inhibitors in prevention-data from the ATAC (Arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res (2003) 163:96-103. doi:10.1007/978-3-642-55647-0_9 discussion 264-106
39. Chlebowski R, Cuzick J, Amakye D, Bauerfeind I, Buzdar A, Chia S, et al. Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. Breast (2009) 18(Suppl 2):S1-11. doi:10.1016/S0960-9776(09)70002-5
40. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 97:1262-71. doi:10.1093/jnci/dji250
41. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol (2008) 9:45-53. doi:10.1016/S1470-2045(07)70385-6
42. Richardson H, Johnston D, Pater J, Goss P. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol (2007) 14:89-96. doi:10.3747/co.2007.117
43. Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma. Breast J (2005) 11:278-80. doi:10.1111/j.1075-122x.2005.21463.x
44. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer (2005) 5:341-54. doi:10.1038/nrc1667
45. Strecker TE, Shen Q, Zhang Y, Hill JL, Li Y, Wang C, et al. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. J Natl Cancer Inst (2009) 101:107-13. doi:10.1093/jnci/djn436
46. Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, et al. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst (2003) 95:1825-33. doi:10.1093/jnci/djg117
47. Lu H, Ladd J, Feng Z, Wu M, Goodell V, Pitteri SJ, et al. Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila) (2012) 5:1036-43. doi:10.1158/1940-6207.CAPR-11-0558
48. Baxevanis CN, Voutsas IF, Gritzapis AD, Perez SA, Papamichail M. HER-2/neu as a target for cancer vaccines. Immunotherapy (2010) 2:213-26. doi:10.2217/imt.09.89
49. Holmes JP, Benavides LC, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol (2008) 26:3426-33. doi:10.1200/JCO.2007.15.7842
50. Carmichael MG, Benavides LC, Holmes JP, Gates JD, Mittendorf EA, Ponniah S, et al. Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer (2010) 116:292-301. doi:10.1002/cncr.24756
51. Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer (2012) 118:2594-602. doi:10.1002/cncr.26574
52. Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, et al. Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res (2009) 15:6327-40. doi:10.1158/1078-0432.CCR-09-1107
53. Szanto A, Narkar V, Shen Q, Uray IP, Davies PJ, Nagy L. Retinoid X receptors: X-ploring their (patho)physiological functions. Cell Death Differ (2004) 11(Suppl 2):S126-43. doi:10.1038/sj.cdd.4401533
54. Wu K, Kim HT, Rodriquez JL, Munoz-Medellin D, Mohsin SK, Hilsenbeck SG, et al. 9-Cis-retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40 T antigen-transgenic mice. Clin Cancer Res (2000) 6:3696-704.
55. Wu K, Kim HT, Rodriquez JL, Hilsenbeck SG, Mohsin SK, Xu XC, et al. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid. Cancer Epidemiol Biomarkers Prev (2002) 11:467-74.
56. Wu K, Zhang Y, Xu XC, Hill J, Celestino J, Kim HT, et al. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res (2002) 62:6376-80.
57. Li Y, Zhang Y, Hill J, Shen Q, Kim HT, Xu X, et al. The rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res (2007) 13:6224-31. doi:10.1158/1078-0432.CCR-06-2681
58. Li Y, Zhang Y, Hill J, Kim HT, Shen Q, Bissonnette RP, et al. The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. Br J Cancer (2008) 98:1380-8. doi:10.1038/sj.bjc.6604320
59. Wolbach SB, Howe PR. Tissue changes following deprivation of fat-soluble a vitamin. J Exp Med (1925) 42:753-77. doi:10.1084/jem.42.6.753
60. Moon RC, Thompson HJ, Becci PJ, Grubbs CJ, Gander RJ, Newton DL, et al. N-(4-hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res (1979) 39:1339-46.
61. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med (1990) 323:795-801. doi:10.1056/NEJM199009203231205
62. Lawrence JA, Adamson PC, Caruso R, Chow C, Kleiner D, Murphy RF, et al. Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations. J Clin Oncol (2001) 19:2754-63.
63. Alvarez RD, Conner MG, Weiss H, Klug PM, Niwas S, Manne U, et al. The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial. Cancer Epidemiol Biomarkers Prev (2003) 12:114-9.
64. Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst (1999) 91:1847-56. doi:10.1093/jnci/91.21.1847
65. Veronesi U, Mariani L, Decensi A, Formelli F, Camerini T, Miceli R, et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol (2006) 17:1065-71. doi:10.1093/annonc/mdl047
66. De Palo G, Mariani L, Camerini T, Marubini E, Formelli F, Pasini B, et al. Effect of fenretinide on ovarian carcinoma occurrence. Gynecol Oncol (2002) 86:24-7. doi:10.1006/gyno.2002.6663
67. Ji Y, Lee HJ, Goodman C, Uskokovic M, Liby K, Sporn M, et al. The synthetic triterpenoid CDDO-imidazolide induces monocytic differentiation by activating the Smad and ERK signaling pathways in HL60 leukemia cells. Mol Cancer Ther (2006) 5:1452-8. doi:10.1158/1535-7163.MCT-06-0136
68. Mazumdar A, Medina D, Kittrell FS, Zhang Y, Hill JL, Edwards DE, et al. The combination of tamoxifen and the rexinoid LG100268 prevents ER-positive and ER-negative mammary tumors in p53-null mammary gland mice. Cancer Prev Res (Phila) (2012) 5:1195-202. doi:10.1158/1940-6207.CAPR-11-0524
69. Chan KC, Knox WF, Gee JM, Morris J, Nicholson RI, Potten CS, et al. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res (2002) 62:122-8.
70. Piechocki MP, Dibbley SK, Lonardo F, Yoo GH. Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu. Int J Cancer (2008) 122:1722-9. doi:10.1002/ijc.23231
71. Wong KK, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev (2010) 20:87-90. doi:10.1016/j.gde.2009.11.002
72. Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, et al. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle (2010) 9:188-97. doi:10.4161/cc.9.1.10407
73. Torres-Arzayus MI, Yuan J, Dellagatta JL, Lane H, Kung AL, Brown M. Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland. Cancer Res (2006) 66:11381-8. doi:10.1158/0008-5472.CAN-06-2316
74. Kim SH, Zukowski K, Novak RF. Rapamycin effects on mTOR signaling in benign, premalignant and malignant human breast epithelial cells. Anticancer Res (2009) 29:1143-50.
75. Mercier I, Camacho J, Titchen K, Gonzales DM, Quann K, Bryant KG, et al. Caveolin-1 and accelerated host aging in the breast tumor microenvironment: chemoprevention with rapamycin, an mTOR inhibitor and anti-aging drug. Am J Pathol (2012) 181:278-93. doi:10.1016/j.ajpath.2012.03.017
76. Litzenburger BC, Kim HJ, Kuiatse I, Carboni JM, Attar RM, Gottardis MM, et al. BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells. Clin Cancer Res (2009) 15:226-37. doi:10.1158/1078-0432.CCR-08-0801
77. Turini ME, DuBois RN. Cyclooxygenase-2: a therapeutic target. Annu Rev Med (2002) 53:35-57. doi:10.1146/annurev.med.53.082901.103952
78. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med (2000) 342:1946-52. doi:10.1056/NEJM200006293422603
79. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology (2006) 131:1674-82. doi:10.1053/j.gastro.2006.08.079
80. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med (2006) 355:885-95. doi:10.1056/NEJMoa061652
81. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 352:1071-80. doi:10.1056/NEJMoa050405
82. Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res (2002) 62:5405-7.
83. Khuder SA, Mutgi AB. Breast cancer and NSAID use: a meta-analysis. Br J Cancer (2001) 84:1188-92. doi:10.1054/bjoc.2000.1709
84. Takkouche B, Regueira-Mendez C, Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst (2008) 100:1439-47. doi:10.1093/jnci/djn324
85. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer (2007) 121:856-62. doi:10.1002/ijc.22717
86. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 310:1642-6. doi:10.1126/science.1120781
87. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res (2006) 66:10269-73. doi:10.1158/0008-5472.CAN-06-1500
88. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle (2009) 8:88-96. doi:10.4161/cc.8.1.7499
89. Anisimov VN, Egormin PA, Bershtein LM, Zabezhinskii MA, Piskunova TS, Popovich IG, et al. Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice. Bull Exp Biol Med (2005) 139:721-3. doi:10.1007/s10517-005-0389-9
90. Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat (2011) 126:215-20. doi:10.1007/s10549-010-1224-1
91. Hadad S, Iwamoto T, Jordan L, Purdie C, Bray S, Baker L, et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat (2011) 128:783-94. doi:10.1007/s10549-011-1612-1
92. Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol (2012) 30:2593-600. doi:10.1200/JCO.2011.39.3769
93. Niraula S, Dowling RJ, Ennis M, Chang MC, Done SJ, Hood N, et al. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat (2012) 135:821-30. doi:10.1007/s10549-012-2223-1
94. Mueck AO, Seeger H, Wallwiener D. Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells. Menopause (2003) 10:332-6. doi:10.1097/01.GME.0000055485.06076.00
95. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, et al. Breast cancer growth prevention by statins. Cancer Res (2006) 66:8707-14. doi:10.1158/0008-5472.CAN-05-4061
96. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Shapiro S. Statin use and the risk of breast and prostate cancer. Epidemiology (2002) 13:262-7. doi:10.1097/00001648-200205000-00005
97. Undela K, Srikanth V, Bansal D. Statin use and risk of breast cancer: a meta-analysis of observational studies. Breast Cancer Res Treat (2012) 135:261-9. doi:10.1007/s10549-012-2154-x
98. Kumar AS, Campbell M, Benz CC, Esserman LJ. A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes. J Clin Oncol (2006) 24:2127. doi:10.1200/JCO.2005.04.9882 author reply 2127-2128
99. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol (2005) 23:8606-12. doi:10.1200/JCO.2005.02.7045
100. Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat (2010) 119:137-44. doi:10.1007/s10549-009-0507-x
101. Higgins MJ, Prowell TM, Blackford AL, Byrne C, Khouri NF, Slater SA, et al. A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res Treat (2012) 131:915-24. doi:10.1007/s10549-011-1858-7
102. Uray IP, Brown PH. Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. Recent Results Cancer Res (2011) 188:147-62. doi:10.1007/978-3-642-10858-7_13
103. Dantzer F, Ame JC, Schreiber V, Nakamura J, Menissier-de Murcia J, de Murcia G. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair. Methods Enzymol (2006) 409:493-510. doi:10.1016/S0076-6879(05)09029-4
104. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 434:913-7. doi:10.1038/nature03443
105. Lips EH, Mulder L, Oonk A, van der Kolk LE, Hogervorst FB, Imholz AL, et al. Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer (2013) 108:2172-7. doi:10.1038/bjc.2013.144
106. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 361:123-34. doi:10.1056/NEJMoa0900212
107. Liang H, Tan AR. Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer. IDrugs (2010) 13:646-56.
108. Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res (2006) 66:362-71. doi:10.1158/0008-5472.CAN-05-1107
109. Litzenburger BC, Creighton CJ, Tsimelzon A, Chan BT, Hilsenbeck SG, Wang T, et al. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res (2011) 17:2314-27. doi:10.1158/1078-0432.CCR-10-1903
110. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov (2006) 5:671-88. doi:10.1038/nrd2062
111. Albanell J, Dalmases A, Rovira A, Rojo F. mTOR signalling in human cancer. Clin Transl Oncol (2007) 9:484-93. doi:10.1007/s12094-007-0092-6
112. Perez-Tenorio G, Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer (2002) 86:540-5. doi:10.1038/sj.bjc.6600126
113. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 3:772-5. doi:10.4161/cbt.3.8.994
114. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 4:335-48. doi:10.1038/nrc1362
115. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev (2004) 18:1926-45. doi:10.1101/gad.1212704
116. Yardley DA. Combining mTOR inhibitors with chemotherapy and other targeted therapies in advanced breast cancer: rationale, clinical experience, and future directions. Breast Cancer (Auckl) (2013) 7:7-22. doi:10.4137/BCBCR.S10071
117. Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol (2012) 13:135-44. doi:10.1016/S1470-2045(11)70397-7
118. Huober J, Fasching PA, Hanusch C, Rezai M, Eidtmann H, Kittel K, et al. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab-results of the randomised GeparQuinto study (GBG 44). Eur J Cancer (2013) 49(10):2284-93. doi:10.1016/j.ejca.2013.02.027
119. Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2012) 366:520-9. doi:10.1056/NEJMoa1109653
120. deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res (2004) 10:8059-67. doi:10.1158/1078-0432.CCR-04-0035
121. De Angel RE, Conti CJ, Wheatley KE, Brenner AJ, Otto G, deGraffenried LA, et al. The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001. Mol Carcinog (2013) 52:446-58. doi:10.1002/mc.21878
122. Andrade-Vieira R, Xu Z, Colp P, Marignani PA. Loss of LKB1 expression reduces the latency of ErbB2-mediated mammary gland tumorigenesis, promoting changes in metabolic pathways. PLoS One (2013) 8:e56567. doi:10.1371/journal.pone.0056567
123. Choi HN, Jin HO, Kim JH, Hong SE, Kim HA, Kim EK, et al. Inhibition of S6K1 enhances glucose deprivation-induced cell death via downregulation of anti-apoptotic proteins in MCF-7 breast cancer cells. Biochem Biophys Res Commun (2013) 432:123-8. doi:10.1016/j.bbrc.2013.01.074
124. Becker MA, Ibrahim YH, Cui X, Lee AV, Yee D. The IGF pathway regulates ERalpha through a S6K1-dependent mechanism in breast cancer cells. Mol Endocrinol (2011) 25:516-28. doi:10.1210/me.2010-0373
125. Stratford AL, Fry CJ, Desilets C, Davies AH, Cho YY, Li Y, et al. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res (2008) 10:R99. doi:10.1186/bcr2202
126. Law JH, Li Y, To K, Wang M, Astanehe A, Lambie K, et al. Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability. PLoS One (2010) 5(9):e12661. doi:10.1371/journal.pone.0012661
127. Bailey RL, Gahche JJ, Miller PE, Thomas PR, Dwyer JT. Why US adults use dietary supplements. JAMA Intern Med (2013) 173:355-61. doi:10.1001/jamainternmed.2013.2299
128. Ogunleye AA, Xue F, Michels KB. Green tea consumption and breast cancer risk or recurrence: a meta-analysis. Breast Cancer Res Treat (2010) 119:477-84. doi:10.1007/s10549-009-0415-0
129. Crew KD, Brown P, Greenlee H, Bevers TB, Arun B, Hudis C, et al. Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer. Cancer Prev Res (Phila) (2012) 5:1144-54. doi:10.1158/1940-6207.CAPR-12-0117
130. Castillo-Pichardo L, Cubano LA, Dharmawardhane S. Dietary grape polyphenol resveratrol increases mammary tumor growth and metastasis in immunocompromised mice. BMC Complement Altern Med (2013) 13:6. doi:10.1186/1472-6882-13-6
131. Khan MA, Chen HC, Wan XX, Tania M, Xu AH, Chen FZ, et al. Regulatory effects of resveratrol on antioxidant enzymes: a mechanism of growth inhibition and apoptosis induction in cancer cells. Mol Cells (2013) 35:219-25. doi:10.1007/s10059-013-2259-z
132. Gullett NP, Ruhul Amin AR, Bayraktar S, Pezzuto JM, Shin DM, Khuri FR, et al. Cancer prevention with natural compounds. Semin Oncol (2010) 37:258-81. doi:10.1053/j.seminoncol.2010.06.014
133. Uzoigwe J, Sauter ER. Cancer prevention and treatment using combination therapy with plant-and animal-derived compounds. Expert Rev Clin Pharmacol (2012) 5:701-9. doi:10.1586/ecp.12.62